JAC Advance Access originally published online on May 26, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy 2004 54(1):211-216; doi:10.1093/jac/dkh278
JAC vol.54 no.1 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea
Department of Infectious Diseases, University Hospital, Malmö, Sweden
* Corresponding author. Tel: +46-40-331000; Fax: +46-40-336279; Email: marlene.wullt{at}skane.se
Objectives: Few treatment options are currently available to treat patients suffering from an initial episode of Clostridium difficile-associated diarrhoea (CDAD).
Patients and methods: A prospective, randomized controlled, double-blind trial was conducted to compare the efficacy of fusidic acid and metronidazole for treatment of patients experiencing a first episode of CDAD. The primary outcomes were clinical cure and clearance of C. difficile toxin determined on days 8–13, and secondary outcomes were clinical recurrence and reappearance of C. difficile toxin evaluated on days 35–40.
Results: Of the patients in the fusidic acid group, 83% were clinically cured in comparison to 93% in the metronidazole group (P=0.116) at the first follow-up visit. Clearance of C. difficile toxin did not differ between the two groups at that time. Clinical recurrence and reappearance of C. difficile toxin were noted in 27% and in 13% of the patients receiving fusidic acid, respectively and in 29% and 10% of those given metronidazole at the second follow-up on days 35–40.
Conclusion: Since three of the four primary and secondary outcomes were almost identical for the two groups, the results indicate that fusidic acid is as effective as metronidazole in curing an initial episode of CDAD and can therefore be considered as an adequate alternative for treatment of this disease.
Keywords: antibiotics , alternative treatments , toxins , pseudomembranous colitis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. M. Williams and R. C. Spencer The management of Clostridium difficile infection Br. Med. Bull., September 1, 2009; 91(1): 87 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Halsey Current and future treatment modalities for Clostridium difficile-associated disease Am. J. Health Syst. Pharm., April 15, 2008; 65(8): 705 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Akerlund, I. Persson, M. Unemo, T. Noren, B. Svenungsson, M. Wullt, and L. G. Burman Increased Sporulation Rate of Epidemic Clostridium difficile Type 027/NAP1 J. Clin. Microbiol., April 1, 2008; 46(4): 1530 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Noren, T. Akerlund, M. Wullt, L. G. Burman, and M. Unemo Mutations in fusA Associated with Posttherapy Fusidic Acid Resistance in Clostridium difficile Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1840 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Noren, M. Wullt, T. Akerlund, E. Back, I. Odenholt, and L. G. Burman Frequent Emergence of Resistance in Clostridium difficile during Treatment of C. difficile-Associated Diarrhea with Fusidic Acid. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3028 - 3032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Aspevall, A. Lundberg, L. G. Burman, T. Akerlund, and B. Svenungsson Antimicrobial Susceptibility Pattern of Clostridium difficile and Its Relation to PCR Ribotypes in a Swedish University Hospital. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1890 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V McFarland Alternative treatments for Clostridium difficile disease: what really works? J. Med. Microbiol., February 1, 2005; 54(2): 101 - 111. [Abstract] [Full Text] [PDF]
|
|